EML4 and non-small cell lung carcinoma: This is in keeping with recent observation made in NSCLC, in which patients with EGFR mutations or EML4–ALK translocations experience a significantly better in-field control compared to those without such mutations or those harboring KRAS mutations instead (14, 15).